Background: Acute erythroid leukemia (AEL), also known as pure erythroid leukemia, is a rare subtype of acute myeloid leukemia (AML) characterized by the proliferation of malignant erythroid precursors. Outcome data at the population level are scarce. Methods: We performed a retrospective analysis of the Surveillance Epidemiology and End Results (SEER) database. All cases with a histologically confirmed diagnosis of acute (pure) erythroid leukemia during the period of 2000–2019 were included in the study. The Kaplan–Meier method was used to perform survival analysis. The significance of differences between overall survival (OS) was analyzed using the log-rank test. Results: In total, 968 patients were included in the study. The median age was 68 years (range 0–95), 62% of patients were males, and 62.5% (n = 605) were treated with chemotherapy. The median OS for <18, 18–49, 50–64, 65–79 and 80+ age groups was 69, 18, 8, 3 and 1 month, respectively (p < 0.0001). Patients who received chemotherapy had significantly improved OS compared to patients who did not, among both adults (p < 0.0001) and children (p = 0.004). There were no significant differences in OS based on sex, race, ethnicity and median household income. Median OS for adults diagnosed in 2000–2004, 2005–2009, 2010–2014, 2015–2019 was 4, 6, 6 and 3 months, respectively, with no significant differences in OS between these groups. Conclusion: AEL occurs in all age groups but is most common in the elderly. Outcomes are poor with current chemotherapeutic agents, with no improvement in the last two decades. This study stresses the urgent need for investigational agents.
Introduction:
Neurolymphomatosis (NL) is an extremely rare manifestation of lymphoproliferative and hematologic malignancies characterized by direct neoplastic infiltration of the peripheral nervous system, and ubiquitously portends poor outcomes with dismal survival. This challenging and infrequent clinical entity is most commonly associated with B-cell non-Hodgkin lymphomas (NHLs), with only a few cases of NL as a presentation of mantle cell lymphoma (MCL) ever reported. The heterogenous clinical features of NL overlap with several more common neurologic sequalae of NHL, a challenge which often leads to delays, and even misdiagnosis, of this aggressive condition. As a diagnostically challenging, rapidly progressive rare disease, there is a paucity of evidence describing the natural clinical course of NL, diagnostic algorithms, prognosis, patient outcomes data, and most crucially, optimal therapeutic management strategies. Aggressive lymphomas may also infiltrate the skin causing secondary cutaneous B-cell lymphoma, an exceptionally rare manifestation of MCL. To the authors’ knowledge, this is the first reported case in the literature describing a patient with MCL presenting with primary neurolymphomatosis and secondary cutaneous MCL.
Case presentation:
A 73-year-old man recently diagnosed with MCL developed painless, ascending weakness, which progressed over weeks to near-complete paralysis. MRI of the lumbar spine was consistent with neurolymphomatosis. Concurrently, he developed erythematous papules and plaques on the face, chest, and proximal upper extremities. Skin biopsy was consistent with cutaneous infiltration of MCL. Treatment with HD-MTX plus R-CHOP therapy produced minimal improvement, and he died three weeks after initiation of therapy.
Conclusions
Neurolymphomatosis and secondary cutaneous MCL are each very rare manifestations of MCL. Rapid, aggressive infiltration of both the nerve roots and skin by MCL represents unusually high-grade disease. This case underscores the importance of high clinical suspicion for neurolymphomatosis in any subtype of lymphoma showing aggressive features. Prognosis is poor, and early intervention is crucial to minimize progression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.